Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.58 - $10.54 $213,756 - $297,228
-28,200 Reduced 40.29%
41,800 $333,000
Q2 2024

Aug 15, 2024

SELL
$8.16 - $22.89 $1.58 Million - $4.44 Million
-194,100 Reduced 73.49%
70,000 $609,000
Q1 2024

May 07, 2024

SELL
$19.93 - $29.71 $5.92 Million - $8.82 Million
-296,900 Reduced 52.92%
264,100 $5.46 Million
Q4 2023

Feb 14, 2024

BUY
$5.71 - $24.13 $2.26 Million - $9.56 Million
396,300 Added 240.62%
561,000 $13 Million
Q3 2023

Nov 14, 2023

BUY
$7.99 - $15.36 $1.01 Million - $1.94 Million
126,200 Added 327.79%
164,700 $1.32 Million
Q2 2023

Aug 11, 2023

BUY
$3.03 - $9.0 $30,602 - $90,900
10,100 Added 35.56%
38,500 $334,000
Q1 2023

May 16, 2023

SELL
$2.28 - $5.04 $14,135 - $31,248
-6,200 Reduced 17.92%
28,400 $83,000
Q4 2022

Feb 14, 2023

SELL
$2.37 - $7.2 $93,615 - $284,400
-39,500 Reduced 53.31%
34,600 $121,000
Q3 2022

Nov 14, 2022

SELL
$6.96 - $11.12 $487,200 - $778,400
-70,000 Reduced 48.58%
74,100 $586,000
Q2 2022

Aug 15, 2022

SELL
$7.25 - $12.71 $226,200 - $396,552
-31,200 Reduced 17.8%
144,100 $1.13 Million
Q1 2022

May 16, 2022

BUY
$8.67 - $14.11 $659,787 - $1.07 Million
76,100 Added 76.71%
175,300 $2.13 Million
Q4 2021

Feb 14, 2022

BUY
$10.18 - $18.4 $173,060 - $312,800
17,000 Added 20.68%
99,200 $1.21 Million
Q3 2021

Nov 15, 2021

BUY
$7.51 - $11.72 $112,650 - $175,800
15,000 Added 22.32%
82,200 $857,000
Q2 2021

Aug 11, 2021

BUY
$8.69 - $11.08 $187,704 - $239,328
21,600 Added 47.37%
67,200 $604,000
Q1 2021

May 17, 2021

BUY
$8.89 - $14.92 $405,384 - $680,352
45,600 New
45,600 $463,000

Others Institutions Holding EYPT

About EyePoint Pharmaceuticals, Inc.


  • Ticker EYPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,072,200
  • Market Cap $357M
  • Description
  • EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...
More about EYPT
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.